Alternative Designs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Article | April 26, 2021 5 Key Takeaways: Insights On Alternative Designs To The Traditional 3+3 Design In Phase 1 Dose Escalation Studies By Abie Ekangaki and Andreas Schreiner Traditionally, Phase 1 trials commonly utilize 3+3 designs to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Studies have shown, however, that two out of three trials employing a 3+3 design failed in identifying the MTD, and better approaches are needed.1 During Premier Research’s recent webinar Alternative Designs to the Traditional 3+3 Design in Phase 1...

Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, attendees will learn about the importance of adopting a suitable dose escalation strategy as well as the benefits and challenges of different dose escalation approaches. The risk of selecting a sub-therapeutic dose as the RP2D is a key limitation of the traditional 3+3 dose-escalation design in Phase 1. TORONTO (PRWEB) February 08, 2021 Phase 1 clinical trials aim to determin...